Clinical Trial

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Name: Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) — clinical trial record (NCT07637734)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: COVE-3

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

Trial Details

NCT Number	NCT07637734
Lead Sponsor	Verrica Pharmaceuticals Inc. Collaborators: Torii Pharmaceutical Co. Ltd., CMIC Co, Ltd. Japan, Canfield Scientific Inc., Medidata Solutions, Veeva Systems, Allucent (US) LLC, Myonex LLC
Conditions	Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Enrollment	300 participants
Start Date	2026-06
Primary Completion	2027-08 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-10